• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:范振兴.硝苯地平缓释片Ⅱ治疗原发性高血压的疗效及评价[J].药学研究,2017,36(12):739-741[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3307次   下载 2481次 本文二维码信息
码上扫一扫!
硝苯地平缓释片Ⅱ治疗原发性高血压的疗效及评价
范振兴
字体:加大+|默认|缩小-
(焦作市中医院,河南 焦作 454100)
摘要:
目的 评价硝苯地平缓释片Ⅱ(伲福达)治疗原发性高血压的疗效。方法选取2016年3月~2017年3月期间本院收治的140例原发性高血压患者作为研究对象,随机分为对照组(68例)和观察组(72例)。对照组采用美托洛尔治疗,观察组采用硝苯地平缓释片Ⅱ治疗,治疗期间监测两组患者血压和心率变化,并比较两组临床疗效和用药安全性。结果治疗后,观察组SBP/DBP指标水平(128.56±10.23/84.24±6.02 mmHg)均显著低于对照组(143.58±11.71/90.47±5.24 mmHg),组间有差异P<0.05。观察组总有效率(94.44%,68/72)显著高于对照组(76.47%,52/68),组间有差异(P<0.05)。观察组不良反应发生率(13.89%,10/72)略高于对照组(11.76%,8/68),但无显著差异(P<0.05)。结论原发性高血压患者应用伲福达治疗效果可靠,可有效提升降压效果,改善患者心率,临床应用安全高效。
关键词:  硝苯地平缓释片Ⅱ  原发性高血压  临床疗效  优越性
DOI:10.13506/j.cnki.jpr.2017.12.015
基金项目:
The efficacy and superiority of the treatment of primary hypertension with Nifedipine Substained-release Tablets Ⅱ
FAN Zhenxing
(Jiaozuo Hospital of Traditional Chinese Medicine,Jiaozuo 454100,China)
Abstract:
ObjectiveTo evaluate the efficacy and superiority of the treatment of primary hypertension. Methods In this study,140 patients with primary hypertension, who were admitted to the hospital in March, 2016, were randomly divided into control group (68 cases) and observation group (72 cases).The control group was treated with metoprolol, and the observation group was treated with the treatment of Nifuda, which monitored the blood pressure and heart rate changes in the two groups during the treatment, and compared the clinical efficacy and drug safety of the two groups.Results After treatment,the SBP/DBP index level of the observation group (128.56 plus or minus 10.23/84.24, plus or minus 6.02 mmHg) was significantly lower than that in the control group (143.58+11.71/90.47 or 0.47 mmHg), and the difference between groups was significant(P<0.05).The incidence of adverse reactions (13.89%,10/72) was slightly higher than the control group (11.76%,8/68),but no significant difference wassignificant(P<0.05).ConclusionThetreatmentof patients with primary hypertension was reliable,which can effectively improve the effect of blood pressure,improve the heart rate of patients,and be safe and effective in clinical application.
Key words:  Nifuda  Primary hypertension  Clinical efficacy  Superiority
今日访问量:2329    总访问量:55338697
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司